Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)
ID: 357175Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357175

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-094.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)" aimed at researching the effects of climate change on cancer risk, prevention, and survivorship. This initiative encourages innovative studies that explore how environmental changes influence cancer risks and healthcare delivery, particularly focusing on health inequities among vulnerable populations. The funding supports a maximum project period of five years with no specified budget limit, and applications can be submitted starting January 5, 2025, with deadlines extending until February 2026. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-094-Full-Announcement.html
    PAR-25-094.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces a funding opportunity (FON: PAR-25-094) aimed at researching the impacts of climate change on the cancer control continuum. This funding opportunity supports innovative studies focused on understanding and mitigating the effects of climate change on cancer risk, prevention, and survivorship. Applicants are encouraged to explore how environmental changes influence cancer risks and healthcare delivery disruptions while emphasizing health inequities among vulnerable populations. The application process begins on January 5, 2025, with various submission due dates extending until February 2026. Eligible organizations include higher education institutions, non-profits, for-profits, and local governments. The maximum project period is five years with no set budget limit. Reviews will assess scientific merit based on significance, innovation, rigor, and the expertise of the investigative teams. Successful proposals must include climate change expertise and may involve diverse research approaches. This initiative is crucial in responding to the growing health challenges posed by climate change and aligning with NIH’s goal to enhance public health through advanced research.
    Similar Opportunities
    Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Impacts of Climate Change Across the Cancer Control Continuum," aimed at supporting innovative research on the effects of climate change on cancer risks, control, and survivorship. This R21 Exploratory/Developmental Research Grant encourages multidisciplinary studies that explore the relationship between climate change and cancer-related health disparities, necessitating collaboration with climate change experts. The grant offers a budget cap of $275,000 for a two-year project period, with applications opening on January 16, 2025, and closing on May 7, 2026. Interested applicants can find more information and application instructions at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity focused on the impacts of climate change across the cancer control continuum, designated as the R01 Clinical Trial Optional grant. This initiative aims to support innovative research that assesses the effects of climate-related changes on cancer risks, prevention, survivorship, and healthcare delivery, with an emphasis on developing interventions to address health disparities and enhancing climate-resilient healthcare systems. The funding opportunity is critical for advancing understanding in this area and promoting multidisciplinary research to tackle significant challenges in cancer care exacerbated by environmental changes. Interested applicants, including higher education institutions, non-profits, and various government entities, must submit their applications by May 7, 2026, and can find additional details and guidelines at the provided NIH link or by contacting grantsinfo@nih.gov.
    Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)" aimed at fostering innovative research on the intersection of climate change and cancer. This R21 Exploratory/Developmental Research Grant seeks to explore various aspects of cancer risks exacerbated by climate change, including environmental influences, healthcare disruptions, and health disparities, with a focus on multidisciplinary approaches and collaboration with climate change experts. The grant supports studies with budgets up to $275,000 over a two-year period, and eligible applicants include higher education institutions, nonprofits, state and local governments, and for-profit organizations. Interested parties should note that the application deadline is May 7, 2026, and can find more information at the provided link or contact NIH Grants Information at grantsinfo@nih.gov.
    Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Exploratory Grants in Cancer Control through the R21 Clinical Trial Optional mechanism, aimed at advancing innovative research in cancer control. This funding opportunity encourages applications focused on behavioral modification, screening, and understanding the etiological factors of cancer, with the goal of developing novel methodologies and tools that can significantly impact population-based cancer research. Grants of up to $275,000 are available for projects lasting up to two years, with application deadlines beginning January 16, 2025, and continuing through 2028. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PA-25-253.html.
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies." This initiative aims to support innovative research projects that investigate the adverse effects of cancer therapies, particularly those that lead to chronic comorbidities or delayed sequelae, with a focus on understanding the underlying mechanisms and developing therapeutic strategies to mitigate these long-term issues. The funding is open to a diverse range of applicants, including educational institutions, non-profits, and foreign organizations, and requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications must be submitted electronically by January 5, 2025, with awards contingent on available funding and merit assessed through NIH's peer-review process. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing the burden of cancer. This funding opportunity focuses on enhancing early detection, prevention, healthcare delivery, and survivorship improvements, explicitly excluding studies related to cancer diagnosis or oncologic therapies. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and tribal organizations, with applications due by 5:00 PM local time on January 5, 2024, and a maximum project period of five years. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-072.html.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing cancer burdens through advancements in early detection, prevention, and healthcare delivery. This funding opportunity, identified as PAR-25-167, specifically excludes trials focused on cancer diagnosis or oncologic therapies in patients, emphasizing the importance of improving public health and clinical practices related to cancer. Eligible applicants include a wide range of organizations, such as academic institutions, non-profits, and tribal governments, with applications due by February 5, 2025. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-167.html.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at supporting the planning of clinical trials that enhance cancer prevention, detection, and survivorship. This program seeks to address critical gaps in preliminary data, participant recruitment strategies, and study designs necessary for finalizing trial protocols, thereby facilitating effective cancer intervention trials aligned with public health goals. Eligible organizations, including higher education institutions and nonprofits, can apply for funding of up to $225,000 per year for a maximum of three years, with a requirement to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of their application. Interested applicants should note the open submission date of January 25, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)." This initiative encourages applications that propose innovative secondary data analyses and integration of existing datasets to address significant scientific questions related to cancer risk, prevention, and treatment outcomes. The program aims to leverage diverse data sources, including clinical, environmental, and genomic datasets, to enhance understanding of cancer and improve public health strategies. Eligible applicants include a wide range of organizations, such as higher education institutions, nonprofit organizations, and tribal governments, with a maximum funding amount of $200,000 and a project duration of up to two years. Interested parties can find more information and application details at the NIH grants website, with the submission deadline set for September 7, 2026.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes" (PAR-23-254). This initiative aims to encourage researchers to conduct innovative analyses of existing datasets, including clinical, genomic, and epidemiological data, to address critical questions related to cancer risk, treatment responses, and health outcomes. By leveraging previously collected data, the program seeks to enhance understanding of cancer-related issues while allowing for a limited generation of new data for validation purposes. Eligible applicants include a wide range of institutions, with funding capped at $350,000 annually for up to five years. Applications will be accepted from October 2023 until June 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.